6'-((1,3,4-thiadiazol-2-yl)amino)-8'-chloro-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 6'-((1,3,4-thiadiazol-2-yl)amino)-8'-chloro-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione
• 英文别名: US10000487, Example 1F；8-chloro-6-(1,3,4-thiadiazol-2-ylamino)spiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
• 化学式: C₁₄H₁₄ClN₅O₂S
• 分子量: 351.816
• InChiKey: OPQXJBWSEQHDPK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基-1,3,4-噻二唑 、 6'-bromo-8'-chloro-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以42%的产率得到6'-((1,3,4-thiadiazol-2-yl)amino)-8'-chloro-2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES INHIBANT L'ACTIVITÉ KINASE DE MNK UTILES POUR LE TRAITEMENT DE DIVERS CANCERS

  摘要：

  公开号：

  WO2017087808A8

文献信息

• Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US10000487B2

  公开（公告）日：2018-06-19

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

  本发明提供了符合式 IA 或式 IB 的化合物及其立体异构体、同系物或药学上可接受的盐的合成、药学上可接受的制剂和用途。 对于式 IA 和式 IB 化合物 A1、A2、A3、A4、W1、W2、Y、X、R1、R2、R3、R4a、R4b、R5a、R5b、R6、R7、R8、R9、R9a、R9b、R10 和下标 n 如说明书中所定义。本发明的式IA和式IB化合物是Mnk的抑制剂，可用于各种治疗应用，包括但不限于炎症和各种癌症的治疗。
• HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145009A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
• [EN] HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES INHIBANT L'ACTIVITÉ KINASE DE MNK UTILES POUR LE TRAITEMENT DE DIVERS CANCERS
  申请人：EFFECTOR THERAPEUTICS INC

  公开号：WO2017087808A8

  公开（公告）日：2017-09-21